Physician profile
Robin M Brady
NPI 1609873942
$4,257.75
in general payments reported to CMS, 2019-2025
23 companies · $909 in 2025
The $909 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $95.27 · 2021: $441 · 2022: $786 · 2023: $850 · 2024: $881 · 2025: $909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,409.10 | 2019-2025 | Total30, Argos, Precision7 |
| Biotissue Holdings INC. | $422.88 | 2019-2025 | |
| Johnson & Johnson Vision Care, INC. | $397.19 | 2022-2025 | Acuvue |
| Carl Zeiss Meditec USA, INC. | $318.48 | 2021 | |
| Bausch & Lomb Americas INC. | $269.17 | 2022-2025 | Infuse, Miebo, Biotrue |
| Carl Zeiss Meditec, INC. | $196.26 | 2019 | |
| Abbvie INC. | $195.44 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $169.19 | 2019-2025 | |
| Oyster Point Pharma, INC. | $150.57 | 2022-2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $144.93 | 2023-2025 | Oxervate |
| Allergan, INC. | $143.27 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $87.83 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $55.30 | 2025 | Xdemvy |
| Coopervision INC. | $43.63 | 2023-2025 | Myday Contact Lens, Biofinity Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $38.60 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $37.88 | 2023 | |
| Harrow Eye, LLC | $33.00 | 2024-2025 | Vevye |
| Astellas Pharma US INC | $31.16 | 2025 | Izervay |
| Genzyme Corporation | $28.46 | 2024 | |
| Integra Lifesciences Corporation | $26.30 | 2024 | Biofix, Biodoptix, Biodfactor |
| Alexion Pharmaceuticals, INC. | $23.79 | 2023 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rxsight INC | $15.92 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.